Physician profile
Allison Moser
NPI 1336539980
$59,926.39
in general payments reported to CMS, 2019-2025
18 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,275 · 2022: $16K · 2023: $12K · 2024: $11K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $9,813 · Consulting Fee: $9,030 · Travel and Lodging: $5,473 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,025 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,542.50 |
| Food and Beverage | $9,813.48 |
| Consulting Fee | $9,030.00 |
| Travel and Lodging | $5,473.49 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,025.00 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $23,085.05 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21,089.55 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Ipsen Biopharmaceuticals, INC | $5,810.67 | 2024-2025 | Iqirvo, Bylvay |
| Gilead Sciences, INC. | $4,455.60 | 2021-2025 | Livdelzi |
| Mirum Pharmaceuticals, INC. | $1,957.00 | 2025 | Livmarli |
| Madrigal Pharmaceuticals | $1,156.39 | 2024-2025 | Rezdiffra, Resmetirom |
| Novo Nordisk INC | $461.36 | 2022-2025 | Wegovy |
| Mallinckrodt Hospital Products INC. | $361.91 | 2023-2025 | Terlivaz |
| Glaxosmithkline, LLC. | $300.15 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $281.18 | 2024 | Voquezna |
| Boston Scientific Corporation | $210.08 | 2025 | General - Biliary Devices |
| Ardelyx, INC. | $142.39 | 2025 | Ibsrela |
| Conmed Corporation | $139.63 | 2025 | Conmed Biliary |
| W. L. Gore & Associates, INC. | $128.22 | 2024 | Viatorr Tips Endoprosthesis W/ Controlled Expansion |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $117.70 | 2023 | Xifaxan |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $113.38 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $91.88 | 2023 | Dupixent |
| Sequana Medical US INC. | $24.25 | 2025 | Alfapump System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Moser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.